Table 2.
Select Pathways Relevant to Human Disease
| Term | # Genes | p-value | Group |
|---|---|---|---|
| hsa04010:MAPK signaling pathway | 19 | 1.3E-02 | Cr-down |
| hsa04350:TGF-beta signaling pathway | 11 | 1.6E-03 | Cr-down |
| hsa04350:TGF-beta signaling pathway | 4 | 7.1E-02 | As-down |
| hsa04360:Axon guidance | 11 | 2.7E-02 | Cr-down |
| hsa04510:Focal adhesion | 21 | 6.4E-05 | Cr-down |
| hsa04510:Focal adhesion | 9 | 2.8E-02 | V-up |
| hsa04510:Focal adhesion | 8 | 7.3E-02 | Ni-down |
| hsa04512:ECM-receptor interaction | 13 | 7.7E-05 | Cr-down |
| hsa04512:ECM-receptor interaction | 6 | 1.8E-02 | V-up |
| hsa04512:ECM-receptor interaction | 6 | 1.9E-02 | Ni-down |
| hsa04810:Regulation of actin cytoskeleton | 18 | 3.3E-03 | Cr-down |
| hsa04910:Insulin signaling pathway | 6 | 1.2E-01 | Cr-up |
| hsa04940:Type I diabetes mellitus | 5 | 2.6E-02 | As-up |
| hsa05200:Pathways in cancer | 25 | 1.6E-03 | Cr-down |
| hsa05210:Colorectal cancer | 10 | 4.8E-03 | Cr-down |
| hsa05211:Renal cellcarcinoma | 9 | 4.7E-03 | Cr-down |
| hsa05212:Pancreatic cancer | 8 | 2.0E-02 | Cr-down |
| hsa05215:Prostate cancer | 8 | 5.5E-02 | Cr-down |
| hsa05220:Chronic myeloid leukemia | 7 | 6.8E-02 | Cr-down |
| hsa05221:Acute myeloid leukemia | 5 | 8.5E-02 | As-up |
| hsa05222:Small cell lung cancer | 8 | 4.3E-02 | Cr-down |
| hsa05222:Small cell lung cancer | 5 | 6.7E-02 | V-up |
| hsa05223:Non-small cell lung cancer | 5 | 7.3E-02 | As-up |
| hsa05223:Non-small cell lung cancer | 4 | 7.6E-02 | V-up |
| hsa05330:Allograft rejection | 4 | 7.1E-02 | As-up |
| hsa05332:Graft-versus-host disease | 5 | 2.0E-02 | As-up |
| hsa05410:Hypertrophic cardiomyopathy (HCM) | 12 | 3.0E-04 | Cr-down |
| hsa05412:Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 9 | 7.3E-03 | Cr-down |
| hsa05414:Dilated cardiomyopathy | 11 | 2.3E-03 | Cr-down |
As/Ni, fold-change cut-off of 1.25; Cr/V, fold-change cut-off of 1.50.